Vorinostat NEW

Description:

Vorinostat, also known by its brand name Zolinza, is a medication used in the treatment of cancer. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. Vorinostat works by interfering with the function of histones, proteins that help package DNA into a compact structure within the cell nucleus. By inhibiting HDACs, vorinostat causes an accumulation of acetylated histones, leading to an open chromatin structure and affecting gene expression. This process can induce cancer cell death (apoptosis), stop their division (cell cycle arrest), reduce metastasis potential, and enhance immune recognition of tumor cells.

Applications of Vorinostat:

• Cutaneous T-cell Lymphoma (CTCL): Vorinostat is primarily approved for the treatment of CTCL in patients who have progressive, persistent or recurrent disease on or following two systemic therapies. CTCL is a rare type of non-Hodgkin lymphoma that affects the skin.

  
  

  
  

Key Benefits:

The significance of vorinostat lies in its novel approach to targeting cancer at the epigenetic level—modifying how genes are expressed without altering the DNA sequence itself. For patients with CTCL or potentially other cancers resistant to conventional treatments, vorinostat offers a new line of therapy by exploiting vulnerabilities unique to cancerous cells’ regulatory mechanisms.

In summary, vorinostat represents an important advancement in oncology as an HDAC inhibitor providing therapeutic benefits particularly for patients with certain types of lymphomas like cutaneous T-cell lymphoma while continuing research aims at expanding its applicability against broader cancer types through understanding and leveraging epigenetic modifications.

Product Forms: Injectable Solution, Oral Capsules/Tablets

Payment method: T/T in advance, Paypal, Western Union, L/C, etc.

Shipping ways: Courier, Air, Sea, Road

Storage Condition: Dry, dark, and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).